Skip to main content

Market Overview

Veracyte Raises $550M In Upsized Equity Offering For Decipher Biosciences Acquisition

  • Veracyte Inc (NASDAQ: VCYT) has priced an upsized underwritten public offering of around 7.4 million common shares at $74 per share, with gross proceeds of approximately $550 million. Earlier, the company announced the equity offering of $400 million.
  • The offer price represents a discount of around 5% from the last close price of $77.87 on Thursday.
  • Underwriters have an option to purchase up to an additional 1.1 million.
  • The offering is expected to close by February 9.
  • Goldman Sachs and SVB Leerink are acting as joint lead book-running managers for the offering.
  • The majority of the proceeds from the offering will be used to finance Decipher Biosciences acquisition.
  • Price Action: VCYT shares closed 5.5% higher at $77.87 on Thursday.

Related Articles (VCYT)

View Comments and Join the Discussion!

Posted-In: Biotech M&A News Offerings General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at